OBJECTIVE: The influence of nevirapine (NVP) on lopinavir (LPV) pharmacokinetics was investigated by a population analysis based on a non-linear mixed-effect modelling method. METHODS: In this analysis, 95 HIV-1 infected patients were studied [52 treated with LPV/ritonavir (400/100 mg twice a day) plus nucleoside reverse transcriptase inhibitors (group A), 22 patients treated with LPV/ritonavir (533.3/133.3 mg twice a day) plus NVP (group B) and 21 patients treated with LPV/ritonavir (400/100 mg twice a day) plus NVP (group C)]. RESULTS: The apparent clearance of LPV [mean+/-SD: 4.56+/-3.94 l h(-1) (group A) versus 7.14+/-1.77 l h(-1) (group B) versus 7.74+/-1.45 l h(-1) (group C)] was significantly (P <0.001) increased by the presence of NVP in the antiretroviral regimen and the mean trough plasma concentration of LPV was reduced in group C relative to group A [mean+/-SD: 2.23+/-1.35 mg/l versus 5.29+/-2.19 mg/l (P < 0.001)]. CONCLUSION: These results suggest an induction of LPV metabolism by NVP.
OBJECTIVE: The influence of nevirapine (NVP) on lopinavir (LPV) pharmacokinetics was investigated by a population analysis based on a non-linear mixed-effect modelling method. METHODS: In this analysis, 95 HIV-1 infectedpatients were studied [52 treated with LPV/ritonavir (400/100 mg twice a day) plus nucleoside reverse transcriptase inhibitors (group A), 22 patients treated with LPV/ritonavir (533.3/133.3 mg twice a day) plus NVP (group B) and 21 patients treated with LPV/ritonavir (400/100 mg twice a day) plus NVP (group C)]. RESULTS: The apparent clearance of LPV [mean+/-SD: 4.56+/-3.94 l h(-1) (group A) versus 7.14+/-1.77 l h(-1) (group B) versus 7.74+/-1.45 l h(-1) (group C)] was significantly (P <0.001) increased by the presence of NVP in the antiretroviral regimen and the mean trough plasma concentration of LPV was reduced in group C relative to group A [mean+/-SD: 2.23+/-1.35 mg/l versus 5.29+/-2.19 mg/l (P < 0.001)]. CONCLUSION: These results suggest an induction of LPV metabolism by NVP.
Authors: Constance A Benson; Steven G Deeks; Scott C Brun; Roy M Gulick; Joseph J Eron; Harold A Kessler; Robert L Murphy; Charles Hicks; Martin King; David Wheeler; Judith Feinberg; Richard Stryker; Paul E Sax; Sharon Riddler; Melanie Thompson; Kathryn Real; Ann Hsu; Dale Kempf; Anthony J Japour; Eugene Sun Journal: J Infect Dis Date: 2002-02-14 Impact factor: 5.226
Authors: M Nikanjam; E G Chadwick; B Robbins; C Alvero; P Palumbo; R Yogev; J Pinto; R Hazra; M L Hughes; B E Heckman; E V Capparelli Journal: Clin Pharmacol Ther Date: 2011-12-21 Impact factor: 6.875
Authors: Kun Wang; David Z D'Argenio; Edward P Acosta; Anandi N Sheth; Cecile Delille; Jeffrey L Lennox; Corenna Kerstner-Wood; Ighovwerha Ofotokun Journal: Clin Pharmacokinet Date: 2014-04 Impact factor: 6.447
Authors: Brian L Robbins; Edmund V Capparelli; Ellen G Chadwick; Ram Yogev; Leslie Serchuck; Carol Worrell; Mary Elizabeth Smith; Carmelita Alvero; Terence Fenton; Barbara Heckman; Stephen I Pelton; Grace Aldrovandi; William Borkowsky; John Rodman; Peter L Havens Journal: Antimicrob Agents Chemother Date: 2008-07-14 Impact factor: 5.191